CN116425830B - 一种具有抗癌活性的小分子肽及其应用 - Google Patents
一种具有抗癌活性的小分子肽及其应用 Download PDFInfo
- Publication number
- CN116425830B CN116425830B CN202310512166.0A CN202310512166A CN116425830B CN 116425830 B CN116425830 B CN 116425830B CN 202310512166 A CN202310512166 A CN 202310512166A CN 116425830 B CN116425830 B CN 116425830B
- Authority
- CN
- China
- Prior art keywords
- small molecular
- peptide
- molecular peptide
- activity
- anticancer activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 27
- 230000001093 anti-cancer Effects 0.000 title claims abstract description 14
- 206010009944 Colon cancer Diseases 0.000 claims abstract description 9
- 208000029742 colonic neoplasm Diseases 0.000 claims abstract description 9
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 6
- 150000003384 small molecules Chemical class 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 3
- 239000003560 cancer drug Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 15
- 238000003786 synthesis reaction Methods 0.000 abstract description 9
- 230000000694 effects Effects 0.000 abstract description 7
- 230000035755 proliferation Effects 0.000 abstract description 7
- 229940041181 antineoplastic drug Drugs 0.000 abstract description 5
- 238000001514 detection method Methods 0.000 abstract description 5
- 229930001118 polyketide hybrid Natural products 0.000 abstract description 5
- 125000003308 polyketide hybrid group Chemical group 0.000 abstract description 5
- 101000979117 Curvularia clavata Nonribosomal peptide synthetase Proteins 0.000 abstract description 4
- 241000187561 Rhodococcus erythropolis Species 0.000 abstract description 4
- 238000011161 development Methods 0.000 abstract description 2
- 101150109417 NRPS gene Proteins 0.000 abstract 1
- 238000005259 measurement Methods 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 102000004196 processed proteins & peptides Human genes 0.000 description 8
- 229930014626 natural product Natural products 0.000 description 7
- 239000000589 Siderophore Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 229910001447 ferric ion Inorganic materials 0.000 description 3
- 108091008053 gene clusters Proteins 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 108010000785 non-ribosomal peptide synthase Proteins 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- FODJWPHPWBKDON-LJQANCHMSA-N (2r)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-[(2-methylpropan-2-yl)oxy]-4-oxobutanoic acid Chemical group C1=CC=C2C(COC(=O)N[C@H](CC(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 FODJWPHPWBKDON-LJQANCHMSA-N 0.000 description 1
- JOOIZTMAHNLNHE-NRFANRHFSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-5-[(2-methylpropan-2-yl)oxycarbonylamino]pentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCCNC(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 JOOIZTMAHNLNHE-NRFANRHFSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- GYSCBCSGKXNZRH-UHFFFAOYSA-N 1-benzothiophene-2-carboxamide Chemical compound C1=CC=C2SC(C(=O)N)=CC2=C1 GYSCBCSGKXNZRH-UHFFFAOYSA-N 0.000 description 1
- VHQALVHKNXDJRY-UHFFFAOYSA-N 1-bromo-2-chloro-4-fluoro-3-methylbenzene Chemical compound CC1=C(F)C=CC(Br)=C1Cl VHQALVHKNXDJRY-UHFFFAOYSA-N 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N Decanoic acid Natural products CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000316848 Rhodococcus <scale insect> Species 0.000 description 1
- 108010019477 S-adenosyl-L-methionine-dependent N-methyltransferase Proteins 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 229930183665 actinomycin Natural products 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000009412 basement excavation Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000012070 whole genome sequencing analysis Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0819—Tripeptides with the first amino acid being acidic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明涉及药物化学领域，涉及一种具有抗癌活性的小分子肽及其应用。通过生物信息平台对红串红球菌D‑1的基因组进行挖掘，发现了新结构的NRPS基因簇，预测出该NRPS合成的非核糖体肽的可能的分子结构，并通过化学合成得到一个小分子肽，经检测，其表现出一定铁载体活性测定，可以抑制人结肠癌HCT116细胞的增值，有新型抗癌药物开发的价值。
Description
技术领域
本发明涉及药物化学领域，涉及一种具有抗癌活性的小分子肽，以及其在制备抑制人结肠癌HCT116细胞增值的药物中的应用。
背景技术
肿瘤对人类健康有着巨大威胁，迄今为止依然是对人类危害最大的高死亡疾病之一，因此发现高效优质的新抗癌药物成为全世界的重要研究课题。非核糖体肽是微生物的次级代谢产物，由非核糖体肽合成酶(NRPS,Nonribosomal Peptide Synthase)合成，结构多样，是天然产物的重要来源之一。在临床领域被广泛应用，如万古霉素、青霉素、博来霉素和放线菌素等。然而，菌株中的大量合成基因簇在实验室常规培养条件下大多是沉默的或表达量很低，很难通过分离得到相应非核糖体肽；另外激活这些沉默基因簇需要针对不同的菌株进行大量的分子遗传学工作，过程繁琐、周期长、费用高，在筛选菌株、分离纯化和表征合成路径等过程中需要耗费大量的时间、精力和金钱。
随着对天然产物合成酶的结构与功能关系的不断深入研究，生物信息学家开发出了一些软件(如antiSMASH等)，根据合成酶的结构来预测其产物，研究者将这些软件的预测结果与化学合成手段结合起来，开发出一种新的发掘天然产物的途径，即合成-生信天然产物(synthetic-bioinformatic natural product，syn-BNP)法。通过生物信息学对基因簇一级序列进行分析，预测化合物的潜在化学结构，然后通过化学合成产生合成预测产物。
本发明对一株红串红球菌D-1进行全基因组测序后，将测序结果导入生物信息数据库进行分析。通过antiSMASH5.0数据库预测出一个红串红球菌NRPS合成的非核糖体肽的可能的分子结构，再经化学合成得到了这些小分子肽，最后进行活性表征，发现其中一个小分子肽对结肠癌细胞的增值具有抑制效果。
发明内容
为加速天然产物的挖掘和丰富天然产物分子库，本发明使用软件预测出一株红串红球菌基因组中一个NRPS合成的非核糖体肽的可能的分子结构，再通过化学合成得到了这些小分子肽，经检测其中一个小分子肽对结肠癌细胞的增值具有抑制效果。
一种具有抗癌活性的小分子肽，化学式为C21H38N4O7(化合物1)，结构式如下：
所述具有抗癌活性的小分子肽可应用于制备抗癌药物。
所述小分子肽对结肠癌细胞的增值具有抑制效果。
本发明的有益效果：
本发明通过对一株红球菌基因簇的挖掘得到了一个小分子肽。对该化合物进行抗癌实验发现，其对结肠癌细胞的增值具有抑制效果。因此，该化合物有望成为抗癌药物的先导化合物并具有良好的开发前景。
附图说明
图1是本发明实施例中抗癌化合物正离子质谱图
图2是本发明实施例中抗癌化合物HPLC谱图
图3是本发明小分子肽铁载体活性结果图
图4是本发明小分子肽对HCT116细胞的抗癌活性结果图
具体实施方式
本发明结合附图和实施例作进一步的说明。实施例中所使用的细胞培养基成分：DMEM培养液，使用前每500ml DMEM加入5ml的L-谷氨酰胺和青霉素-链霉素双抗，再加25ml的胎牛血清。在37℃、5％二氧化碳浓度条件下培养细胞。
本发明的小分子肽根据其结构式可以直接通过全化学合成多肽技术制得，本实施例仅提供其一种具体合成思路作为说明，并非对其的限制：从固相树脂上从C端开始三个氨基酸逐一接上去，依次是Fmoc-Orn(Boc)-OH,Fmoc-Gly-OH,Fmoc-D-Asp(OtBu)-OH,最后脱掉Fmoc保护基团，接上癸酸，然后用TFA把多肽从树脂上切下来并同时去除侧链保护。得到的多肽粗品经过HPLC纯化，然后冻干。
成品经过了HPLC分析纯度和MS确认分子量。
所得产物的正离子质谱及HPLC谱图如图1、2所示，本实例中将该小分子肽命名为ZJURENRP1-FA，简称1-FA。该小分子肽具有抑制HCT116细胞增殖的作用，是一种具有应用前景的抗癌化合物。
(一)化合物的结构分析
本发明抗癌化合物为白色固体，易溶于二甲基亚砜，甲醇、微溶于水。
ESI-MS m/e 458.52([M+H]+)。
(二)铁载体活性检测
采用CAS检测法进行检测，原理是CTAB、络天青S和三价铁离子结合形成蓝色化合物，当铁载体遇到这个蓝色化合物时，由于铁载体对三价铁离子的亲和力更高抢走铁离子，导致溶液颜色由蓝色转变为橙黄色或红色。1-FA的铁载体活性如图3所示。水杨酸作为阳性对照，可以看到水杨酸和蓝色溶液混合后，颜色发生了显著变化变成红色，与CK组(在CAS检测液中加入DMSO)加入1-FA的检测液颜色发生了变化，从蓝色变成了浅红色，说明1-FA具有铁载体活性。
(三)抗癌活性检测
1、供试癌细胞
HCT116
2、抑癌活性的测定
抑癌活性采用MTT法。按照细胞传代步骤，消化细胞制成细胞悬浮液，以100μL6000个细胞铺在96孔板中，过夜培养。加入浓度梯度的1-FA，每孔100μL，设置三个重复，37℃培养48h。弃去孔内培养液，每孔加入50μL MTT(1mg/ml)，37℃避光孵育3h，再向每孔加入150μL DMSO处理30分钟。紫色结晶体彻底溶解后，通过酶标仪检测各孔570nm处的吸光值。
实验结果如图4所示，可以看出，相对于CK组(不加入1-FA培养细胞24h)，加入本发明的小分子肽化合物的实验组中结肠癌细胞HCT116数量明显降低，由此可知，该化合物对结肠癌细胞的增值具有抑制效果，有望将其应用于抗癌药物的制备中。
本发明的内容不限于具体实施方式所列举，本领域普通技术人员通过阅读本发明说明书而对本发明技术方案采取的任何等效的变换，均为本发明的权利要求所涵盖。
Claims (3)
1.一种具于抗癌活性的小分子肽，其化学式为C21H38N4O7，结构式如下：
。
2.如权利要求1所述的小分子肽的应用，其特征在于：所述小分子肽应用于制备抗结肠癌药物。
3.一种抑癌药，其特征在于，含有如权利要求1所述的小分子肽。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310512166.0A CN116425830B (zh) | 2023-05-08 | 2023-05-08 | 一种具有抗癌活性的小分子肽及其应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310512166.0A CN116425830B (zh) | 2023-05-08 | 2023-05-08 | 一种具有抗癌活性的小分子肽及其应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116425830A CN116425830A (zh) | 2023-07-14 |
| CN116425830B true CN116425830B (zh) | 2024-03-26 |
Family
ID=87085562
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310512166.0A Active CN116425830B (zh) | 2023-05-08 | 2023-05-08 | 一种具有抗癌活性的小分子肽及其应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116425830B (zh) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1988001173A1 (en) * | 1986-08-21 | 1988-02-25 | The Mount Sinai School Of Medicine | Benzylthioether-linked solid support-bound thiol compounds and method for peptide synthesis |
| CN1739788A (zh) * | 2004-03-31 | 2006-03-01 | 新加坡国立大学 | Trip－br功能的调节和治疗增殖性紊乱的方法 |
| CN107205901A (zh) * | 2014-11-11 | 2017-09-26 | 强生消费者公司 | 氨基酸衍生物及其用途 |
| CN108101960A (zh) * | 2017-12-15 | 2018-06-01 | 湖北工业大学 | 一种具有ace抑制活性和抗肿瘤的多肽分子及其制备方法 |
| KR20180106795A (ko) * | 2017-03-17 | 2018-10-01 | 강원대학교산학협력단 | 한우 저분자 추출물 또는 한우 유래 펩타이드를 함유하는 대장암 개선, 예방 또는 치료용 조성물 |
| CN113621054A (zh) * | 2021-08-31 | 2021-11-09 | 北京化工大学 | 一种具有抑制人结肠癌细胞（ht-29细胞）增殖作用的鸡源胶原肽及其制备与应用 |
| CN115850388A (zh) * | 2022-11-29 | 2023-03-28 | 深圳市人民医院 | 一种lncRNA编码的抗癌肽AC115619-22AA及应用 |
-
2023
- 2023-05-08 CN CN202310512166.0A patent/CN116425830B/zh active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1988001173A1 (en) * | 1986-08-21 | 1988-02-25 | The Mount Sinai School Of Medicine | Benzylthioether-linked solid support-bound thiol compounds and method for peptide synthesis |
| CN1739788A (zh) * | 2004-03-31 | 2006-03-01 | 新加坡国立大学 | Trip－br功能的调节和治疗增殖性紊乱的方法 |
| CN107205901A (zh) * | 2014-11-11 | 2017-09-26 | 强生消费者公司 | 氨基酸衍生物及其用途 |
| KR20180106795A (ko) * | 2017-03-17 | 2018-10-01 | 강원대학교산학협력단 | 한우 저분자 추출물 또는 한우 유래 펩타이드를 함유하는 대장암 개선, 예방 또는 치료용 조성물 |
| CN108101960A (zh) * | 2017-12-15 | 2018-06-01 | 湖北工业大学 | 一种具有ace抑制活性和抗肿瘤的多肽分子及其制备方法 |
| CN113621054A (zh) * | 2021-08-31 | 2021-11-09 | 北京化工大学 | 一种具有抑制人结肠癌细胞（ht-29细胞）增殖作用的鸡源胶原肽及其制备与应用 |
| CN115850388A (zh) * | 2022-11-29 | 2023-03-28 | 深圳市人民医院 | 一种lncRNA编码的抗癌肽AC115619-22AA及应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116425830A (zh) | 2023-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Burke et al. | Spliceosome profiling visualizes operations of a dynamic RNP at nucleotide resolution | |
| Chen et al. | Dual targeting of DDX3 and eIF4A by the translation inhibitor rocaglamide A | |
| EP3040417A1 (en) | Macrocyclic peptide, method for producing same, and screening method using macrocyclic peptide library | |
| Zafrir-Ilan et al. | Eight novel serine proteases inhibitors from a water bloom of the cyanobacterium Microcystis sp. | |
| Raibaut et al. | Accelerating chemoselective peptide bond formation using bis (2-selenylethyl) amido peptide selenoester surrogates | |
| Seth et al. | Molecular portrait of high productivity in recombinant NS0 cells | |
| Konno et al. | Active site-directed proteomic probes for adenylation domains in nonribosomal peptide synthetases | |
| Meier et al. | Proteomic analysis of polyketide and nonribosomal peptide biosynthesis | |
| Jia et al. | pSILAC method coupled with two complementary digestion approaches reveals PRPF39 as a new E7070-dependent DCAF15 substrate | |
| Zhao et al. | Comprehensive analysis for histone acetylation of human colon cancer cells treated with a novel HDAC inhibitor | |
| Townsend et al. | CycLS: Accurate, whole-library sequencing of cyclic peptides using tandem mass spectrometry | |
| Della Sala et al. | Identification of the biosynthetic gene cluster of thermoactinoamides and discovery of new congeners by integrated genome mining and MS-Based molecular networking | |
| Todorov et al. | Synthesis, characterization and anticonvulsant activity of new series of N-modified analogues of VV-hemorphin-5 with aminophosphonate moiety | |
| CN116425830B (zh) | 一种具有抗癌活性的小分子肽及其应用 | |
| Liu et al. | 5 (4H)-Oxazolones as effective aminoacylation reagents for the 3′-terminus of RNA | |
| Fouque et al. | Metal ions induced secondary structure rearrangements: mechanically interlocked lasso vs. unthreaded branched-cyclic topoisomers | |
| Chapman et al. | Isopenicillin N synthase: crystallographic studies | |
| Grummitt et al. | Active-site-mediated elimination of hydrogen fluoride from a fluorinated substrate analogue by isopenicillin N synthase | |
| Durano et al. | Histone acetylation landscape in S. cerevisiae nhp6ab mutants reflects altered glucose metabolism | |
| Trézéguet et al. | The mitochondrial ADP/ATP carrier: functional and structural studies in the route of elucidating pathophysiological aspects | |
| Strangman et al. | Identification of the new chymotrypsin inhibitor micropeptin 996 by metabolomics-guided analysis | |
| Zhang et al. | A Semisynthesis Platform for the Efficient Production and Exploration of Didemnin‐Based Drugs | |
| CN116789759A (zh) | 一种具有抗结肠癌活性的多肽及其应用 | |
| Sergiev et al. | Non-stressful death of 23S rRNA mutant G2061C defective in puromycin reaction | |
| Li et al. | A bicyclic pentapeptide-based highly potent and selective pan-SIRT1/2/3 inhibitor harboring Nε-thioacetyl-lysine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |